Why AI matters at this scale

Fisher Clinical Services, a part of Thermo Fisher Scientific, is a global leader in providing clinical trial supply chain solutions. The company manages the complex logistics of storing, packaging, labeling, and distributing investigational drugs and biological materials to trial sites worldwide. With operations spanning temperature-controlled transportation, regulatory compliance, and inventory management, Fisher ensures that clinical trials run smoothly, maintaining product integrity and patient safety. As a large enterprise with over 10,000 employees, its scale introduces both immense complexity and significant opportunities for efficiency gains through automation and data intelligence.

In the pharmaceutical sector, clinical trials are extraordinarily costly and time-sensitive. Delays or errors in the supply chain can set back drug development by months, costing sponsors millions and delaying patient access to new therapies. For a company of Fisher's size, managing thousands of simultaneous shipments across diverse geographies and strict temperature requirements generates vast amounts of data. AI technologies can process this data to uncover patterns, predict outcomes, and automate decision-making in ways that manual processes cannot match. At this scale, even marginal improvements in forecasting accuracy or risk reduction can translate into substantial financial and operational benefits.

Three concrete AI opportunities with ROI framing

1. Predictive Demand Forecasting for Trial Supplies: Machine learning models can analyze historical trial data, patient enrollment rates, and site activation timelines to predict drug demand with high precision. This reduces overproduction and waste of expensive biologics, which can cost over $1 million per trial. ROI is direct: a 10-20% reduction in wasted materials significantly cuts costs for sponsors and improves Fisher's service margin.

2. Automated Regulatory Document Processing: Natural language processing (NLP) can automate the review and management of clinical trial protocols, informed consent forms, and country-specific regulatory submissions. This reduces manual labor, accelerates startup timelines, and minimizes compliance risks. ROI comes from faster trial initiation (potentially weeks sooner) and lower administrative overhead.

3. Proactive Risk Management in Cold Chain Logistics: Integrating AI with IoT sensors from shipping containers allows real-time analysis of temperature, humidity, and location data. Predictive algorithms can flag potential deviations before they occur, enabling rerouting or intervention. This preserves drug efficacy, avoids costly reshipments, and enhances sponsor trust. ROI is achieved by reducing loss events and associated penalties.

Deployment risks specific to large enterprises (10,001+ employees)

Implementing AI in a large, regulated organization like Fisher presents unique challenges. First, integration with legacy enterprise systems (e.g., SAP, Oracle) can be slow and costly, requiring extensive customization and data pipeline development. Second, the highly regulated nature of clinical trials demands that AI models be fully validated and explainable to meet FDA and EMA standards, adding complexity to deployment. Third, change management across a global workforce requires careful training and communication to ensure adoption without disrupting existing workflows. Finally, data silos across different regions or business units may hinder the aggregation of high-quality datasets needed for effective AI training. Mitigating these risks requires a phased approach, starting with pilot projects in less critical areas, investing in robust data governance, and partnering with technology providers experienced in life sciences compliance.